We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.


registration required

for more website access

This content can only be viewed by subscribers and registered users of Investors Chronicle.

Subscribe or register free today

GSK battles against austerity

The extent of sales problems caused by austerity measures in Europe was made fully clear in GlaxoSmithKline 's (GSK) results, with declining revenues and profits in key markets very much the theme. But the company's pipeline is in much better shape, with 14 different drugs expected to report Phase III data during the next two years. So, with further savings in the supply chain to come, investors can afford to wait for an upturn.

registration required

visible-status-Standard story-url-GSK prelims 2013 6 Feb 2013.xml

By Julian Hofmann,
06 February 2013

Print this article

Related Companies

Advertiser reports

Register today and get...

Register today and get...
Please note terms & conditions apply